Embattled pharma company GSK may be celebrating the continued availability of its once-blockbuster drug Avandia on the market, but it’s bemoaning the fact that the FDA is putting the breaks (halting recruitment) on a safety trial it has begun initiating in an effort to restore positive PR for its troubled drug. As part of its 20-12 ruling to keep the drug on the pharma market, the FDA is also requiring the IOM to investigate the ethics surrounding GSK’s commission of the trial.The study, though not officially canceled, is suspended while the FDA continues to soak in the data and come to its own definitive conclusions regarding the safety of Avandia. | LINK

Related Posts Within Doctor Pundit:

1. FDA Considers Ending Troubled GSK Drug’s Involvement in Safety Study Add yet another blow to GSK’s once-blockbuster diabetes drug, Avandia...
2. Diabetes Drug Once Again under Scrutiny A couple of weeks before the FDA meets to discuss...
3. Report: Pharma Company Covered Up Known Cardiovascular Risks of Drug GSK (then known as SmithKline Beecham) knew in a 1999...
4. Report: FDA Pharma Approval Process Undermines Patient Access to Timely Healthcare A conservative health and public policy think tank reports on...
5. FDA: Keep Avandia on Market, Impose Ponderous Restrictions on Use The FDA has announced today Avandia’s official indication. After months...